'While higher prices may create some financial burden for patients and caregivers in the short term, uninterrupted access to treatment remains the greater priority.'
Eight commonly prescribed anti-cancer drugs will soon enter India's National List of Essential Medicines (NLEM).
Dabur Pharma, a leading player in the domestic oncology segment, is busy finalising its marketing strategies for EU, the US and Australia.
The government regulates prices of all other medicines.
